In this section, we will review currently available data regarding: (i) the ability of both normal and tumor thyroid cells to secrete CXCL8; (ii) the direct/indirect pro-tumorigenic effects of CXCL8, as shown by in vitro and in vivo studies in thyroid cancer cells; and (iii) the pharmacologic strategies for lowering CXCL8 secretion and/or for targeting its effects in thyroid cancer. The gene discussed is CXCL8; the disease is neoplasm.